BioSpace News Archive

As per Precedence Research, the U.S. behavioral health market size is forecast to hit US$ 132.4 billion by 2027 with a growing CAGR of 5.3% during the forecast period 2021 to 2027.

The pharmaceutical manufacturing market size is estimated to hit around US$ 1,050.26 billion by 2029 and growing at a CAGR of 12.8% over the forecast period 2021 to 2030.

The global prosthetics and orthotics market size is estimated to hit US$ 14.63 billion by 2029 and growing at a CAGR of 5% from 2021 to 2030.

Precedence Research predicts, the pain management therapeutics market size is estimated to reach US$ 101.27 billion by 2029 and growing at a CAGR of 4.3% from 2022 to 2030.

NORDIC PHARMA, a SEVER Life Sciences company, announced today the submission of a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet® for the treatment of severe disabling active rheumatoid arthritis (RA) and symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.

Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces that Joshua Schafer has been appointed as interim Chairman of the Pharnext Board of Directors with immediate effect.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reported its consolidated annual financial results for 2021 and provided an update on key achievements, as well as the Company’s outlook for 2022 for its immunotherapies in immuno-oncology and immuno-inflammation.

The Multiple Myeloma Research Foundation has appointed George Mulligan, Ph.D., as its new Chief Scientific Officer effective immediately.

Ketamine Wellness Centers (KWC), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has expanded its treatment options to include SPRAVATO® nasal spray.

Avinger, Inc. today announced the issuance of three new U.S. patents in March 2022 and provided an update on the expansion of its intellectual property portfolio.